EFFICACY THAT DELIVERS

Only ABRAXANE + gemcitabine is proven to significantly improve OS across a broad range of patients3,a

Overall survival in MPACT trial ABRAXANE + gemcitabine (8.5 months, 95% CI: 7.9-9.5) vs gemcitabine alone (6.7 months, 95% CI: 6.0-7.2); P <0.0001 - Kaplan-Meier graph Overall survival in MPACT trial ABRAXANE + gemcitabine (8.5 months, 95% CI: 7.9-9.5) vs gemcitabine alone (6.7 months, 95% CI: 6.0-7.2); P <0.0001 - Kaplan-Meier graph
  • aPatient performance status ranged from ECOG 0-2, with no upper age limit (age range: 27-86 years).3
  • bStratified using Cox proportional hazard model.
  • cBased on a stratified log-rank test (stratified by geographic region, KPS, and presence of liver metastasis).
  • aPatient performance status ranged from ECOG 0-2, with no upper age limit (age range: 27-86 years).3
  • bStratified using Cox proportional hazard model.
  • cBased on a stratified log-rank test (stratified by geographic region, KPS, and presence of liver metastasis).
  • ORR (Overall Response Rates)

    RESPONSE MATTERS:
    ORR ASSESSED BY INDEPENDENT REVIEW

    ABRAXANE (125 mg/m2 QW3/4) + gemcitabine more than tripled ORR vs gemcitabine alone
    Overall response rates: ABRAXANE + gemcitabine vs gemcitabine Overall response rates: ABRAXANE + gemcitabine vs gemcitabine
    CLOSE THE TAB
  • PFS (Progression-Free Survival)

    ABRAXANE + GEMCITABINE
    SIGNIFICANTLY IMPROVED PFSa

    49% increase in median PFS with ABRAXANE (125 mg/m2 QW3/4) + gemcitabine
    compared with gemcitabine alone3
    49% increase in median PFS with ABRAXANE (125 mg/m2 QW3/4)
    + gemcitabine compared with gemcitabine alone3
    Progression-free survival: ABRAXANE + gemcitabine vs gemcitabine Progression-free survival: ABRAXANE + gemcitabine vs gemcitabine
    • aBased on independent radiological reviewer assessment.
    • bStratified using Cox proportional hazard model.
    • cBased on a stratified log-rank test (stratified by geographic region, KPS, and presence of liver metastasis).
    CLOSE THE TAB
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL